Webinar 17/06/24, page-20

Couldn't be happier with the addition of RM, absolutely love her attitude. Keeps the SP on the fridge, "her family is counting on it as much as ours."

For mine, right person at the right time. Feels like she's here to make partnerships happen and she has a proven track record. The 2 large partnerships she mentioned both happened last year.

https://www.novartis.com/au-en/news/media-releases/novartis-telstra-health-and-monash-university-join-forces-tackle-australias-number-one-killer-heart-disease
https://pharmainfocus.com.au/news_m.asp?newsid=21306

Interesting her spinout was acquired by Sanofi. Sanofi has a partnership with Innate pharma for their NK cell engager. The partnership formed in 2016 on the back of pre-clinical data. Sanofi must like what they see because they have since added to the partnership.

They just released data from their phase 1/2 basket trial of blood cancers, including relapsed or refractory acute myeloid leukaemia (AML), B‑cell acute lymphoblastic leukaemia (B-ALL), and high-risk myelodysplastic syndromes (HR-MDS).

Recent results were from the AML patients. The patients had received an average of two prior therapies, although the range extended from one to 10. I'd expect our results to be substantially better moving the patients to the frontline.

"The latest data comes from a group of 59 patients all with AML, other than one subject who had HR-MDS, and looked at a range of doses of the drug, given as a monotherapy by intravenous infusion between 0.01 and 6.0 mg/kg. The patients had received an average of two prior therapies, although the range extended from one to 10."

"The best response rate was seen with the 1.0 mg/kg dose group, with five AML patients achieving either complete remission (CR) or CR with incomplete haematological recovery. The median treatment duration was 7.9 weeks, with durable CR – of 10 months or more - seen in three patients, with two remaining on maintenance therapy as of the data cut-off.“

"Ongoing studies are focused on further demonstrating the potential of the NK cell engager in patients with leukaemia,” said Peter Adamson, Sanofi’s global development head for oncology. “We look forward to sharing data from these trials at future scientific meetings.”

https://pharmaphorum.com/news/new-data-eha-backs-sanofi-innates-nk-cell-engager
https://www.innate-pharma.com/products/pipeline-overview